This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perrotti, D. Articles by Neviani, P. Search for Related Content PubMed PubMed Citation Articles by Perrotti, D. Articles by Neviani, P.

From mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way

Authors' Affiliation: The Molecular Biology and Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio

Requests for reprints: Danilo Perrotti, Polaris Innovation Centre, The Ohio State University Medical Center, 2001 Polaris Parkway, Columbus, OH 43240. Phone: 614-293-5739; Fax: 614-293-5952; E-mail: danilo.perrotti{at}osumc.edu.

Abstract

Altered mRNA metabolism is a feature of many cancers including blast crisis chronic myelogenous leukemia. Indeed, loss of function of many tumor suppressors regulating cell proliferation, survival, and differentiation results from aberrant mRNA processing, nuclear export, and/or translation. Here, we summarize the effects of increased BCR/ABL oncogenic activity on the expression and function of RNA binding proteins (e.g., FUS, hnRNP A1, hnRNP E2, hnRNP K, and La/SSB) with posttranscriptional and translational regulatory activities and their importance for the phenotype of BCR/ABL-transformed hematopoietic progenitors. We also provide evidence that these studies not only advance our understanding on the molecular mechanisms contributing to tumor/leukemia emergence, maintenance, and/or progression but they also serve for the identification of novel molecular targets useful for the development of alternative therapies for imatinib-resistant and blast crisis chronic myelogenous leukemia and, perhaps, for other cancers characterized by similar alterations in the mRNA metabolism.

This article has been cited by other articles:

				A. M. Eiring, P. Neviani, R. Santhanam, J. J. Oaks, J. S. Chang, M. Notari, W. Willis, C. Gambacorti-Passerini, S. Volinia, G. Marcucci, et al. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis Blood, January 15, 2008; 111(2): 816 - 828. [Abstract] [Full Text] [PDF]